受体表达与临床亚型对乳腺癌基线[18F]FDG摄取的影响:系统综述与荟萃分析
该系统综述与荟萃分析纳入50项研究,评估乳腺癌原发肿瘤[18F]FDG摄取(SUVmax)与ER、PR、HER2、Ki-67表达及临床亚型的关系。结果显示,ER阴性、PR阴性、HER2阳性及Ki-67阳性肿瘤的SUVmax显著更高;Luminal A型SUVmax最低,三阴性乳腺癌最高,HER2过表达呈中等效应。
要点
- ER阴性、PR阴性、HER2阳性及Ki-67阳性乳腺癌原发肿瘤的SUVmax显著更高。
- Luminal A型SUVmax显著低于Luminal B型、HER2阳性型及三阴性乳腺癌。
- Luminal B型SUVmax显著低于三阴性乳腺癌;Luminal B型与HER2阳性型、HER2阳性型与三阴性乳腺癌之间差异不显著。
核心结论
- 乳腺癌原发肿瘤SUVmax在ER阴性、PR阴性、HER2阳性及Ki-67阳性患者中显著更高。
- Luminal型肿瘤SUVmax最低,三阴性乳腺癌最高,HER2过表达呈中等效应。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed和Embase中比较乳腺癌患者IHC表达阴性组与阳性组之间SUVmax的研究。
- 由两名评价者独立筛选研究并提取数据,最终纳入50项研究。
- 采用DerSimonian-Laird随机效应模型估计标准化均数差(SMD)及95%置信区间(CI),P值小于或等于5%为统计学显著。
主要发现
- ER阴性组31项研究,SMD 0.66(95%CI 0.56-0.77),P<0.0001,SUVmax显著高于ER阳性组。
- PR阴性组30项研究,SMD 0.56(95%CI 0.40-0.71),P<0.0001,SUVmax显著高于PR阳性组。
- HER2阳性组32项研究,SMD -0.29(95%CI -0.49至-0.10),P=0.0043,SUVmax显著高于HER2阴性组。
- Ki-67阳性组19项研究,SMD -0.77(95%CI -0.93至-0.61),P<0.0001,SUVmax显著高于Ki-67阴性组。
- Luminal A型分别与Luminal B型(11项研究,SMD -0.49,95%CI -0.68至-0.31,P=0.0001)、HER2阳性型(15项研究,SMD -0.91,95%CI -1.21至-0.61,P<0.0001)及三阴性乳腺癌(17项研究,SMD -1.21,95%CI -1.57至-0.85,P<0.0001)比较,SUVmax均显著更低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To quantify the relationship between [18F]FDG uptake of the primary tumour measured by PET-imaging with immunohistochemical (IHC) expression of ER, PR, HER2, Ki-67, and clinical subtypes based on these markers in breast cancer patients. METHODS: PubMed and Embase were searched for studies that compared SUVmax between breast cancer patients negative and positive for IHC expression of ER, PR, HER2, Ki-67, and clinical subtypes based on these markers. Two reviewers independently screened the studies and extracted the data. Standardized mean differences (SMD) and 95% confidence intervals (CIs) were estimated by using DerSimonian-Laird random-effects models. P values less than or equal to 5% indicated statistically significant results. RESULTS: Fifty studies were included in the final analysis. SUVmax is significantly higher in ER-negative (31 studies, SMD 0.66, 0.56-0.77, P < 0.0001), PR-negative (30 studies, SMD 0.56; 0.40-0.71, P < 0.0001), HER2-positive (32 studies, SMD - 0.29, - 0.49 to - 0.10, P = 0.0043) or Ki-67-positive (19 studies, SMD - 0.77; - 0.93 to - 0.61, P < 0.0001) primary tumours compared to their counterparts. The majority of clinical subtypes were either luminal A (LA), luminal B (LB), HER2-positive or triple negative breast cancer (TNBC). LA is associated with significantly lower SUVmax compared to LB (11 studies, SMD - 0.49, - 0.68 to - 0.31, P = 0.0001), HER2-positive (15 studies, SMD - 0.91, - 1.21 to - 0.61, P < 0.0001) and TNBC (17 studies, SMD - 1.21, - 1.57 to - 0.85, P < 0.0001); and LB showed significantly lower uptake compared to TNBC (10 studies, SMD - 0.77, - 1.05 to - 0.49, P = 0.0002). Differences in SUVmax between LB and HER2-positive (9 studies, SMD - 0.32, - 0.88 to 0.24, P = 0.2244), and HER2-positive and TNBC (17 studies, SMD - 0.29, - 0.61 to 0.02, P = 0.0667) are not significant. CONCLUSION: Primary tumour SUVmax is significantly higher in ER-negative, PR-negative, HER2-positive and Ki-67-positive breast cancer patients. Luminal tumours have the lowest and TNBC tumours the highest SUVmax. HER2 overexpression has an intermediate effect.
引用
- de Mooij CM, Ploumen RAW, Nelemans PJ, et al. The influence of receptor expression and clinical subtypes on baseline [18F]FDG uptake in breast cancer: systematic review and meta-analysis. EJNMMI Res. 2023. PMID: 36689007. doi:10.1186/s13550-023-00953-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。